(NASDAQ: AUTL) Autolus Therapeutics's forecast annual revenue growth rate of 100.12% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.8%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.37%.
Autolus Therapeutics's revenue in 2026 is $51,128,000.On average, 14 Wall Street analysts forecast AUTL's revenue for 2026 to be $37,265,382,906, with the lowest AUTL revenue forecast at $31,695,003,930, and the highest AUTL revenue forecast at $46,668,225,200. On average, 13 Wall Street analysts forecast AUTL's revenue for 2027 to be $63,674,781,176, with the lowest AUTL revenue forecast at $48,454,046,649, and the highest AUTL revenue forecast at $89,144,693,646.
In 2028, AUTL is forecast to generate $116,208,804,399 in revenue, with the lowest revenue forecast at $77,104,371,387 and the highest revenue forecast at $156,646,615,274.